Menu

Press Releases

Sangamo BioSciences Presents Clinical Data From SB-728-T HIV Study Demonstrating Long-Term Immune Reconstitution and Reduction in the HIV DNA Reservoir In Subjects with Long-Term Infection

, , , ,

Data Demonstrate ZFN-dependent CCR5 Modification of Long-lived Central Memory and Stem-like T-cells RICHMOND, Calif., Nov. 4, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of clinical data from its program to develop a ZFP Therapeutic® for HIV/AIDS.  The data demonstrate a reduction in the HIV DNA reservoir since receiving SB-728-T in seven of nine HIV-infected subjects […]

New Study Finds Robotic-Assisted Lung Surgery Offers Improved Patient Outcomes Compared to Open Surgery

, , , , ,

SUNNYVALE, Calif., Nov. 4, 2013 (GLOBE NEWSWIRE) — A new study comparing open surgery, video-assisted thoracic surgery (VATS), and robotic-assisted surgery to remove diseased lung tissue found that robotic-assisted surgery is associated with significantly lower death rates, lower overall complication rates, and shorter hospital stays compared with open surgery. Researchers also concluded that robotic-assisted surgery is an […]

Roche and Polyphor join efforts to combat multi-drug-resistant bacterial infections

, , ,

Basel, 4 November 2013 – Roche licenses investigational antibiotic POL7080 from Polyphor. POL7080 targets Pseudomonas species with a novel mode of action. This “superbug” bacterium is commonly found in hospitals and has evolved to become resistant to many antibiotic treatments. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Polyphor Ltd., a privately held pharmaceutical company, announced today […]

FDA approves Roche’s Gazyva (obinutuzumab) for people with previously untreated chronic lymphocytic leukemia (CLL)

, , ,

Gazyva demonstrated an 84 percent reduction in the risk of disease worsening or death when combined with chemotherapy compared to chemotherapy alone Gazyva is the first medicine approved with the FDA’s Breakthrough Therapy Designation Basel, 1 November 2013 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved […]

Alliance showcases shared commitment to type 1 diabetes community; kicks off activities for T1Day observance Nov. 1

, , , ,

MINNEAPOLIS and NEW YORK and INDIANAPOLIS, Nov. 1, 2013 /PRNewswire/ — News Highlights: Medtronic and Lilly Diabetes become first ever national presenting sponsors of the #JDRF Walk to Cure #Diabetes Medtronic, Lilly Diabetes help fund more than $500K for #T1D research through #JDRF Walk to Cure #Diabetes national sponsorship Medtronic, Lilly Diabetes’ #JDRF Walk to Cure #Diabetes national sponsorship announcement kicks off #T1Day […]

Novartis Group calls on FDA to maintain the well-established naming policy for all biologics to help ensure patient safety

, ,

Basel, Switzerland, October 30, 2013 – Novartis announced today it has filed a Citizen Petition with the US Food and Drug Administration (FDA), urging the Agency to require that a biosimilar share the same INN as the reference product. Novartis files Citizen Petition with FDA, urging uniform approach to use of international nonproprietary names (INN) for […]

FedEx and Cardinal Health Form Strategic Alliance to Offer Premier Healthcare 3PL Solutions

, ,

New Relationship Gives Customers More Options for Managing Their Supply Chains MEMPHIS, Tenn., and Dublin, Ohio, Oct. 29, 2013 – FedEx Corp. (NYSE: FDX) and Cardinal Health, (NYSE:CAH) announced today that they have formed a strategic alliance that will enable the companies to leverage their market-leading capabilities to provide 3PL solutions. By combining the global […]

Sangamo BioSciences Presents Clinical Data From HIV Study Demonstrating Sustained Control Of Viremia

, , , ,

Reduction of Viral Load at or Below Limit of Detection Ongoing at 14 Weeks  Additional Presentations of Preclinical Data at Annual Meeting of European Society of Gene and Cell Therapy (ESGCT) RICHMOND, Calif., Oct. 28, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of new data demonstrating sustained control of HIV viral load (VL) at […]

Novartis Hosts Competition to Create Novel Mobile Solutions for Heart Failure Caregivers

, ,

Every 30 seconds, someone in the US is hospitalized for heart failure1; mobile solutions could play a role to help manage this disease Novartis Mobile Health Challenge attracted more than 200 companies and developers who competed for cash prizes Winning mobile solutions designed to provide caregivers with novel tools to navigate daily challenges of caring […]

Valeant Pharmaceuticals Announces Settlement Agreement With Anacor

, , ,

LAVAL, Quebec, Oct. 28, 2013 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that it has entered into a settlement agreement with Anacor Pharmaceuticals to resolve all outstanding disputes between them, including the previously disclosed disputes involving Anacor and Valeant’s subsidiaries, Dow Pharmaceutical Sciences, Inc. (Dow) and Medicis Pharmaceutical Corporation. […]

«‹ 38 39 40 41›»